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ContractilitySarcoplasmic reticulum (SR) Ca2+ release plays an essential role in mediating cardiac myocyte contraction.
Depolarization of the plasma membrane results in inﬂux of Ca2+ through L-type Ca2+ channels (LTCCs)
that in turn triggers efﬂux of Ca2+ from the SR through ryanodine receptor type-2 channels (RyR2). This
process known as Ca2+-induced Ca2+release (CICR) occurs within the dyadic region, where the adjacent
transverse (T)-tubules and SR membranes allow RyR2 clusters to release SR Ca2+ following Ca2+ inﬂux
through adjacent LTCCs. SR Ca2+ released during systole binds to troponin-C and initiates actin–myosin
cross-bridging, leading to muscle contraction. During diastole, the cytosolic Ca2+ concentration is restored
by the resequestration of Ca2+ into the SR by SR/ER Ca2+-ATPase (SERCA2a) and by the extrusion of Ca2+
via the Na+/Ca2+-exchanger (NCX1). This whole process, entitled excitation–contraction (EC) coupling, is
highly coordinated and determines the force of contraction, providing a link between the electrical and
mechanical activities of cardiac muscle. In response to heart failure (HF), the heart undergoes maladaptive
changes that result in depressed intracellular Ca2+ cycling and decreased SR Ca2+ concentrations. As a result,
the amplitude of CICR is reduced resulting in less force production during EC coupling. In this review, we dis-
cuss the speciﬁc proteins that alter the regulation of Ca2+ during HF. In particular, we will focus on defects in
RyR2-mediated SR Ca2+ release. This article is part of a Special Issue entitled: Heart failure pathogenesis and
emerging diagnostic and therapeutic interventions.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Excitation–contraction (EC) coupling represents a signaling cascade
that allows the cardiac action potential to trigger myocyte contraction
[1]. Depolarization of the cardiomyocyte membrane leads to activation
of voltage-gated L-type Ca2+ channels (LTCC) located in plasma
membrane invaginations known as transverse (T)-tubules. Ca2+ inﬂux
through LTCC triggers amuch greater release of Ca2+ from the sarcoplas-
mic reticulum (SR) via the ryanodine receptor type-2 (RyR2), a process
known as Ca2+-induced Ca2+ release (CICR) [2] (Fig. 1). This abrupt el-
evation in the cytosolic Ca2+ concentration allows Ca2+ to bind to tropo-
nin C, triggering the release of troponin I (TnI) from the myoﬁlament,
initiating contraction of cardiomyocytes. During muscle relaxation,ure pathogenesis and emerging
logy and Biophysics, and Dept.
f Medicine, One Baylor Plaza,
61; fax: +1 713 798 3475.
).
rights reserved.cytosolic Ca2+ is actively pumped back into the SR via sarco/endoplasmic
reticulum Ca2+-ATPase 2a (SERCA2a) and extruded from
cardiomyocytes via the Na+/Ca2+ exchanger (NCX) [3,4].
Heart failure (HF) is a major cause of morbidity and mortality in
Western countries [5]. It is a physiological state in which cardiac output
does notmeet the demands of the body. Classically, systolic HF is caused
by a reduction in ejection fraction and has higher mortality, compared
with HF with preserved ejection fraction [6]. In this review, we will
focus on the role of alterations in Ca2+ handling proteins in the patho-
genesis of HFwith reduced ejection fraction. In response toHF, the heart
undergoes maladaptive changes that ultimately result in depressed in-
tracellular Ca2+ cycling and decreased SR Ca2+ concentrations (Fig. 1).
Thus, subsequent action potentials lead to depressed CICR, releasing
less Ca2+ and producing less force during EC coupling. Depressed CICR
can result from a reduction in (1) trigger Ca2+ current through LTCC,
(2) reuptake of Ca2+ into the SR, and/or (3) SR Ca2+ release through
RyR2. Over time, these alterations contribute to reduced SR Ca2+
loading, and as such, interfere with the frequency-dependent enhance-
ment of myocyte contractility. In this review, we discussed speciﬁc
alterations in Ca2+ handling proteins associated with the pathogenesis
Fig. 1. Schematic representation of changes in type 2 ryanodine receptors (RyR2) and related proteins in heart failure (HF). Left, represents Ca2+ handling in a cell from normal
heart, and right, represents Ca2+ handling in a cell from a failing heart. 1) shows increased RyR2 activity represented by a wide open RyR2 due to post-translational modiﬁcation
by increased protein kinase A (PKA) and Ca2+/CaM-dependent protein kinase II (CaMKII) activity, reduced protein phosphatases (PP) 1 and PP 2A activity, reduced junctophilin 2
(JPH2) leading to abnormalities in T-tubule structure and increased oxidation by reactive oxygen species (ROS), 2) represents complex changes in L-type Ca2+ channel (LTCC) as
discussed in the text, 3) represents reduced SR/ER Ca2+-ATPase (SERCA2a) activity and corresponding increased phospholamban (PLN) and sarcolipin (SLN) activity, and 4) rep-
resents increased Na+/Ca2+ exchanger (NCX) activity, in heart failure. ↑ represents increase and ↓ represents decrease.
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post-translational regulation during HF.
2. Regulation of ryanodine receptors during excitation–contraction
coupling
RyR2 represents the primary channel mediating the intracellular
Ca2+ release that triggers cardiomyocyte contraction during EC cou-
pling [7]. This homotetrameric transmembrane protein with a molec-
ular weight of 565-kDa per monomer is located on the SR membrane
[8]. The amplitude of Ca2+ release via RyR2 is strongly modulated by
secondary messengers (Ca2+, Mg2+, cAMP) and various intracellular
proteins. One major regulatory subunit interacting with RyR2 is the
12.6-kDa cytosolic FK506-binding protein (FKBP12.6), also known
as calstabin2 [9,10]. FKBP12.6, a peptidyl-prolyl cis-trans isomerase,
tightly associates with RyR2, stabilizing its closed conformational
state and facilitating channel closure [11,12]. Other accessory pro-
teins that bind to RyR2 and inhibit channel open probability include
calmodulin and sorcin [13,14]. Moreover, our studies have recently
revealed that a structural protein, junctophilin-2 (JPH2), binds to
RyR2 and inhibits its activity levels [15].
3. Altered RyR2 regulation in HF
In addition to regulation by accessory and structural proteins,
posttranslational modiﬁcations of RyR2, such as oxidation [16,17],
S-nitrosylation [18–20], and phosphorylation [21–23] have also
been shown to regulate channel activity. The open probability of
RyR2 is strongly regulated by protein kinases that phosphorylate dis-
tinct residues on the channel, and phosphatases that dephosphorylate
RyR2 channel subunits. Several such enzymes are associated with the
RyR2 channel macromolecular complex, including protein kinase A
(PKA), Ca2+/CaM-dependent protein kinase II (CaMKII), andphosphatases, PP1 and PP2A, which allow for rapid and selective reg-
ulation of the channel activity [21,22,24,25]. Several studies have
been conducted to determine the relative importance of each of
these regulatory proteins, especially PKA and CaMKII, in modulating
RyR2 activity in the failing heart [26–31]. Results of these studies
are discordant regarding the relative importance of CaMKII versus
PKA in modulating RyR2 activity. Our recent work suggests that this
apparent discordance may be due to differences in pathophysiological
mechanisms in ischemic versus non-ischemic HF [28]. In the sections
below, we have discussed in detail the current state of knowledge.
3.1. Regulation of RyR2 by PKA phosphorylation in HF
One of the ﬁrst reported changes in RyR2 regulation associated
with HF pathogenesis was altered PKA phosphorylation [21]. This
discovery by the Marks lab led to many related studies on
phosphorylation-dependent regulation of RyR2 in healthy and dis-
eased hearts. Many, but not all, studies have demonstrated increased
phosphorylation of the main PKA phosphorylation site on RyR2, ser-
ine 2808 (S2808) in HF [21,26,28,32–36]. Chronically increased
S2808 phosphorylation on RyR2 may promote diastolic SR Ca2+
leak that, in turn, depletes SR Ca2+ stores and reduces EC coupling
[37,38].
Recently, some new insights were obtained in genetically altered
mice in which the S2808 site was either constitutively activated
(S2808D) or genetically inactivated (S2808A). Shan et al. demonstrat-
ed that S2808D knock-in mice developed spontaneous HF and
exhibited increased mortality after experimental myocardial infarc-
tion (MI), as a result of severe SR Ca2+ leak [29]. Conversely, Wehrens
et al. showed that S2808A knock-in mice were relatively protected
from the development of HF following experimental MI [35]. In con-
trast, another study showed that, although MI increased phosphory-
lation of RyR2 at the S2808 site, genetic inhibition of S2808
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ing ischemic HF [26]. The reasons for these discrepant ﬁndings re-
main unknown at this time, although differences in the time-points
chosen for the assessment of cardiac function after MI and differences
in the size of the infarction may have contributed.
In contrast to the above ﬁndings, a recent study by Benkusky et al.
[36] demonstrated that S2808A knock-in mice were not protected
from non-ischemic HF due to pressure overload. Consistent with this
ﬁnding, Respress et al. [28] showed that there was only a
non-signiﬁcant increase in S2808 phosphorylation on RyR2 in WT
mice subjected to non-ischemic HF. In this particular model of
non-ischemic HF caused by transverse aortic constriction, no
signiﬁcant changes were observed in the phosphorylation status of
S2808 on RyR2, as well as the PKA phosphorylation site S16 on
phospholamban (PLN). Consistent with these ﬁndings in animals, pa-
tients with non-ischemic HF also did not show increases in the phos-
phorylation status of S2808 on RyR2 [28]. Thus, it seems that the
potential involvement of S2808 phosphorylation on RyR2 in HF devel-
opment may depend on the disease etiology, with current evidence
suggesting that enhanced PKA-dependent phosphorylation of S2808
on RyR2 may only play a role in the development of ischemic HF.
3.2. Regulation of RyR2 by CaMKII in HF
In addition to PKA, RyR2 channels are also phosphorylated by
CaMKII, which primarily phosphorylates a nearby site (serine 2814)
on RyR2 [22,27]. Hoch et al. were among the ﬁrst group of scientists
to demonstrate increased expression of the CaMKII-δC isoform in car-
diac muscle of patients with HF [39]. Following this report, Zhang et
al. showed that cardiac-speciﬁc overexpression of CaMKII-δC in mice
causes abnormal Ca2+ handling and development of HF [40]. Con-
versely, Zhang et al. showed that overexpression of AC3-I, a peptide
inhibitor of CaMKII, delayed the onset of HF in mice following MI
[41]. Various studies have demonstrated that increased RyR2 phos-
phorylation by CaMKII upregulation contributes to enhanced SR
Ca2+ leak in HF [37,38,42]. The role of CaMKII phosphorylation of
RyR2 in HF is further supported by the ﬁndings that pressure overload
increases CaMKII phosphorylation of RyR2, enhances diastolic SR
Ca2+ release events, and promotes HF in mice, and the fact that this
phenotype can be reversed by genetic inhibition of CaMKII activity
in CaMKII-δ deﬁcient mice [43,44]. These studies suggest a dominant
role of abnormal CaMKII regulation of RyR2 in HF.
Our recent studies provide additional insights into the importance
of the S2814 phosphorylation site on RyR2 as a downstream target of
CaMKII in HF. Respress et al. [28] demonstrated that patients with
non-ischemic HF but not ischemic HF, exhibited increased levels of
CaMKII phosphorylation of RyR2. Genetic inhibition of CaMKII phos-
phorylation of S2814 on RyR2 (S2814A) in mice protected against
pressure overload induced non-ischemic HF but not against
MI-induced ischemic HF [28]. Taken together, these studies identiﬁed
RyR2 as a downstream target of CaMKII in HF and suggest that CaMKII
phosphorylation of RyR2 is important in the pathogenesis of
non-ischemic HF [28].
3.3. Regulation of RyR2 by PP1 and PP2A in HF
The fact that RyR2 phosphorylation can be chronically increased in
HF despite down regulation of β-adrenergic receptors raised the idea
that RyR2 hyperphosphorylation might be the result of altered local
signaling, rather than defective global cAMP and Ca/CaM-dependent
signaling. Seminal work by Marx et al. revealed that RyR2 is in fact
a macromolecular channel complex that contains protein kinases
(PKA, CaMKII) and protein phosphatases (PP1, PP2A) targeted to
the pore-forming channel subunits [21]. Although PP1 and PP2A
have similar catalytic mechanisms, substrate recognition mechanisms
on RyR2 for PP1 and PP2A may be distinct. For example, Huke et al.showed that whereas PP1 can dephosphorylate both S2808 (the
major PKA site) and S2814 (the major CaMKII site), PP2A can only de-
phosphorylate the S2814 site on RyR2 [45].
There is also emerging evidence that reduced PP activity may con-
tribute to altered RyR2 phosphorylation levels in HF. For example, Ai
et al. demonstrated reduced amounts of PP1 and PP2A within the
RyR2 complex in rabbits with non-ischemic HF [37]. In addition,
pharmacological inhibition of PP2A activity in cardiomyocytes results
in hyperphosphorylation of RyR2 at site S2814, promoting diastolic
Ca2+ release events [46,47]. Together, these studies suggest that re-
duced PP1 and PP2A activity in the RyR2 macromolecular complex
can underlie the abnormal Ca2+ handling seen in the failing heart
[46,47]. However, similar to the controversy regarding the role of
PKA and CaMKII in the speciﬁc etiologies of HF, recent studies by
Belevych et al. showed that levels of PP1A catalytic subunits did not
change in a tachycardia-induced HF dog model, whereas both regula-
tory and catalytic subunits of PP2A were downregulated in this model
[46]. This is in contrast to other studies which showed reduced protein
levels and PKA phosphorylation of inhibitor-1 (I-1, an inhibitor of
phosphatase-1) in human failing hearts, implicating the role of altered
PP1 activity [48]. Overexpression of a truncated, constitutively active
I-1 form reversed contractile dysfunction in previously failingmyocytes
[49,50]. Moreover, genetic overexpression of I-1 in mice enhanced con-
tractility, leading to an increase in RyR2 phosphorylation at S2814, but
not S2808, and increased diastolic SR Ca2+ release events and
arrhythmogenicity [51].
In addition to PPs, cyclic nucleotide phosphodiesterases (PDEs)
have also been identiﬁed in the RyR2 complex, where they regulate
intracellular levels of cAMP and cGMP [21]. Within the cardiac PDE
family, multiple isoforms are expressed varying in mechanistic action
as well as subcellular location [52]. Of the six major classes, PDEs 2/3/
4 regulate the activity of PKA through the hydrolyzing of cAMP [53].
Speciﬁcally, PDE4B mediates cAMP at the level of the plasma mem-
brane [54], while PDE3A and PDE4D are thought to directly regulate
cAMP levels on the SR [55]. Therefore, these isoforms aid in the con-
trol of β-adrenergic stimulation, PKA-mediated phosphorylation of
RyR2, and cardiomyocyte contraction [33]. In contrast, PDE4 inhibi-
tion increases the frequency of SR Ca2+ release [33], and the
incidence of atrial ﬁbrillation upon β-adrenergic stimulation,
suggesting that PDE is another critical regulator of RyR2 phosphoryla-
tion through cAMP/PKA activation. Based on the current literature,
lack of PDE-mediated regulation of PKA through dysregulation of
β-adrenergic receptor/cAMP compartmentalization also contributes
to RyR2 hyperphosphorylation, cardiac remodeling, and HF. Speciﬁ-
cally, it has been shown that reduced levels of PDE4D3 in patients
with HF may contribute to RyR2 hyperphopshorylation and channel
defects [33]. In summary, the exact roles of PP1, PP2A, and PDE4 in
RyR2 phosphorylation and HF pathogenesis remains to be elucidated,
although emerging data suggest that the balance between kinase,
phosphatase, and phosphodiesterase activity is altered in HF.
3.4. RyR2 and oxidation in HF
Redox signaling serves as another important posttranslational
modulator of RyR2 open probability [16,17,56]. Each monomer of
RyR2 contains roughly 90 cysteine residues, 20 of which are in a
reduced state under normal conditions. Many of these cysteines
are potential targets for various redox modiﬁcations, including
S-nitrosylation, S-glutathionylation, and disulﬁde crosslinking
[18]. Endothelial nitric oxide synthase (eNOS), which is localized
to caveolae where it compartmentalizes with beta-adrenergic re-
ceptors and LTCC, allows NO to inhibit β-adrenergic-induced
inotropy [57–60]. In contrast, neuronal NOS (nNOS) has an oppo-
site, facilitative effect on contractility, wherein, it stimulates SR
Ca2+ release via RyR2 [18,19]. This opposite effect is further
evidenced by the observation that nNOS deﬁciency reduces
2428 S. Ather et al. / Biochimica et Biophysica Acta 1832 (2013) 2425–2431inotropic response, whereas eNOS deﬁciency enhances contractili-
ty due to corresponding changes in SR Ca2+ release [20]. In addi-
tion to redox modulation by nitrosylation, cardiac SR is reported
to contain NADH oxidase as well as NOX2 oxidase (that utilizes
NADPH instead of NADH) both of which regulate the RyR2 complex
under physiological conditions [61–63].
In HF, a shift in the cellular redox potential creates a more oxidized
state with increase in reactive oxygen species (ROS) and NO [64–66].
This shift in balance has a signiﬁcant impact on SR Ca2+ handling pro-
teins affecting EC coupling, in particular RyR2 [64–66]. In the initial
phases of HF, increase in NO levels may be an adaptive response to
myocardial dysfunction, elevated cytokines, and increase in ROS
[64]. This is evidenced by the observation that S-nitrosylation (>3
sites per monomer) leads to reversible RyR2 activation [18]. However,
as HF becomes more advanced, oxidation of proteins supersedes
nitrosylation. Whereas, nitrosylation is a reversible process, oxidation
leads to irreversible activation (beyond a certain threshold) [18].
Moreover, oxidation of reactive thiols induces cross-linking between
RyR2 subunits resulting in channel activation that can be reversed
by S-nitrosylation [56]. In addition, nNOS deﬁciency leads to an in-
crease in ROS that may lead to oxidation of reactive thiols on RyR2
[67]. Thus, whereas S-nitrosylation seems to control the basal redox
state of the channel and is an adaptive process in the initial stages of
HF, oxidation is a pathological process found in advanced HF [16]. Fi-
nally, in addition to the direct effects of ROS on RyR2, oxidation can
also activate RyR2 by means of CaMKII oxidation and activation [68].
Recent evidence suggests that CaMKII activity can be enhanced byme-
thionine oxidation of M281/M282 [68]. These ﬁndings highlight the
complex and interdependent nature of various posttranslational mod-
iﬁcations of RyR2 that can alter channel activity during HF. For more
information regarding the role of oxidative stress in HF, please see
the review article by Tsutsui et al. [69].3.5. RyR2 and structural proteins in HF
Structural remodeling also plays an important role in the patho-
genesis of HF [70]. One of the important aspects of structural remod-
eling at the cellular level is the remodeling of T-tubules, which can
indirectly impact Ca2+ handling [71]. HF leads to a reduction in the
overall density as well as irregularities in T-tubule patterning
[70,72,73]. Speciﬁcally, the changes include an increase in longitudi-
nal component and a reduction in the transverse component [74].
As indicated above, proper CICR is critical for contraction in
cardiomyocytes. T-tubules ensure that LTCC and RyR2 are in close
proximity of each other for optimal CICR. Disruptions in the dyadic
distance leads to desynchronized CICR and a reduction in the force
of contractility [15,70,71,74]. An important role of T-tubule disruption
in HF pathogenesis is also indicated by the fact that mechanical
unloading reverses T-tubule remodeling and normalizes CICR in the
left ventricle in a rat model of ischemic HF, as well as in the right ven-
tricle in a rat model of pulmonary artery hypertension [70,75]. In ad-
dition to its effect on CICR, T-tubule disruption in HF also alters
propagation of action potential, further hampering EC coupling [76].
Recently, our lab and Wei et al. [15,73] found that junctophilin-2
(JPH2), a structural protein, may be a critical mediator of T-tubule re-
modeling in HF. Our data revealed that an acute reduction in JPH2
levels leads to variability in dyadic distance, loss of EC coupling
gain, resulting in aberrant SR Ca2+ leak through RyR2 and eventual
HF development [15]. Complementary to our results, Wei et al.
showed that in the early stages of HF in a rat model of HF, the T tubule
disruption was accompanied by reduction in JPH2 levels [73]. Overall,
there is strong evidence that alterations in T-tubule structure alter SR
Ca2+ regulation and play an important role in the pathogenesis of HF.
These structural changes are intertwined with electrical remodeling,
and together, have become critical therapeutic targets for thetreatment of HF. Current research is aimed at determining whether
downregulation of JPH2 is in response to or an actual cause of HF.
4. L-Type Ca2+ channels in HF
EC coupling in failing hearts can also be depressed due to altered
regulation of the LTCC (CaV1.2) on the plasma membrane. The LTCC
is composed of a pore-forming α1C subunit and the auxiliary subunits
β, α2δ, and γ, which are involved in channel trafﬁcking to the sarco-
lemma and modulation of the voltage-dependence of channel gating
[77,78]. While some investigators have reported an increase in ICa,L
in left ventricular hypertrophy and HF, others have demonstrated
an unaltered or downregulated LTCC in HF [78]. This contradiction
is evidenced by the fact that although the single-channel activity of
LTCC is enhanced in failing heart, whole-cell current is unaltered
[79]. A recent study showed that failing hearts have impaired
Cav1.2 trafﬁcking [80,81]. These investigators demonstrated that
‘Bridging integrator 1’ (BIN1), a membrane scaffolding protein that
causes Cav1.2 to trafﬁc to T tubules, is reduced in human failing
cardiomyocytes. Hong et al. reported that although the total Cav1.2
was not changed in the failing heart, lack of BIN1 leads to reduced
abundance of Cav1.2 channels in T-tubules that in turn reduces ICa,L
[81]. In a more recent study, Goonasekera et al. showed that reduced
LTCC led to a compensatory elevation in neuroendocrine stimulation
and RyR2-mediated SR Ca2+ leak, which actually increased the gain
of ECC [82]. This enhanced ECC gain resulted in pathologic cardiac hy-
pertrophy and failure through calcineurin/nuclear factor of activated
T cells (calcineurin/NFAT) signaling. Although these ﬁndings require
further investigation, they suggest complex reciprocal signaling
between the LTCC and intracellular pro-hypertrophic signaling
pathways.
5. SERCA2a in HF
The cardiac isoform of SERCA (SERCA2a) controls the rate of cyto-
solic Ca2+ removal and the reﬁlling of SR Ca2+ load in cardiomyocytes.
Decreased expression and activity of SERCA2a leads to impaired SR
Ca2+ uptake and reduced SR Ca2+ load in cardiomyocytes, which, in
turn, compromises SR Ca2+ release and impairs cardiomyocyte con-
tractility [83]. Reduced SERCA2a function is a hallmark of failing hearts
and has been found inmany experimental models of HF and end-stage
HF patients [83]. Normalization of SERCA2a function has been shown
to increase contractility and improve hemodynamics along with sur-
vival in rodent and large animal models of HF [84–88]. These animal
studies have led to SERCA2a gene therapy that is currently being eval-
uated in a clinical trial [83].
The activity of SERCA2a is directly regulated by accessory sub-
units, including phospholamban (PLN) and sarcolipin (SLN). PLN, a
small protein comprised of 52 amino acid residues, has proven to be
the major inhibitory regulator of SERCA2a. Similar to the regulation
of RyR2, PKA and CaMKII also play an important role in the regulation
of PLN, as they can phosphorylate PLN at sites Ser16 and Thr17, re-
spectively [89,90]. In its dephosphorylated state, PLN exists predomi-
nantly as monomers that bind to and inhibit SERCA2a activity. On the
other hand, phosphorylated PLN forms pentameric complexes, which
have a lower afﬁnity for SERCA2a, allowing for enhanced activity. The
role of PLN in the pathogenesis of HF has been conﬁrmed in animal
models where inhibition of PLN restored SR Ca2+ load, delaying the
progression of cardiac dysfunction and pathological remodeling
[90,91]. However, loss of PLN did not rescue other genetic mouse
models of HF, questioning a causal association between the two [92].
In addition to PLN, SLN, a 31-amino acid protein, also regulates
SERCA2a activity [93]. SLN can bind to SERCA2a through PLN and
cause a “superinhibition” of SERCA2a [94,95]. Transgenic mice with
cardiac-speciﬁc overexpression of SLN exhibit an impairment of
cardiac contractility and ventricular hypertrophy, associated with a
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isolated papillary muscle [96]. Moreover, mice lacking both PLN and
SLN display increased SERCA2a pump activity, resulting in elevations
in the amount of SR Ca2+ load and systolic Ca2+ transient [97]. How-
ever, over time, constitutive activation of SERCA2a in this mutant
model becomes detrimental to cardiac function [97]. These ﬁndings
suggest the importance of the dynamic regulation of SERCA2a by
PLN and/or SLN in the maintenance of cardiac contractility under
normal conditions and during pathological states.
Furthermore, the small ubiquitin-like modiﬁer type 1 (SUMO1) has
also been shown to regulate the activity of SERCA2a through a novel
posttranslational modiﬁcation, termed SUMOylation, which is thought
to increase the intrinsic activity of SERCA2a ATPase [98,99]. Kho et al.
found that the levels of SERCA2a and SUMO1 were reduced in animal
models of HF and in failing cardiomyocytes isolated from HF patients
[99]. In the same study, using a transverse aortic constriction-induced
HF mouse model, the authors demonstrated that SERCA2a levels could
be restored by increasing SUMO1 expression using gene transfer, there-
by improving cardiac performance and decreasing mortality.
6. NCX1 in HF
Another membrane protein essential in Ca2+ homeostasis in
cardiomyocytes is the Na+/Ca2+-exchanger type 1 (NCX1). During
diastole, NCX1 removes 1 Ca2+ ion from the cytosol in exchange for
inﬂux of 3 Na+ ions. As such, this represents another major mecha-
nism, along with SERCA2a, of restoring cytosolic Ca2+ to pre-
systolic levels. HF is characterized by elevated cytosolic Ca2+ levels
due to reduction in CICR and reduced SERCA2a activity as detailed
above, which in turn leads to a compensatory increase in NCX1 ex-
pression and activity [100–103]. However, the upregulation of NCX1
may become maladaptive over long periods of time due to several
reasons. First, in contrast to SERCA2a, NCX1 does not replenish SR
Ca2+ stores and, thus, does not help in restoring the diminished
CICR. Second, upregulation and/or increased activity of NCX1 can be
potentially pro-arrhythmogenic [102–105]. Overall, the role of NCX
is unclear in the pathogenesis of contractile dysfunction in HF but
its detrimental role in causing lethal arrhythmias in the setting of
HF has been established by several studies.
7. Conclusion
Several studies have conﬁrmed that diastolic Ca2+ leak from the
SR is increased in myocytes isolated from animals, as well as patients,
with HF. In addition, there is abundant evidence that remodeling of
the RyR2 macromolecular channel complex and changes in posttrans-
lational modiﬁcations contribute to channel dysfunction that underlie
the SR Ca2+ leak. The enhanced SR Ca2+ leak observed in HF can im-
pair cardiac performance, although defects in SERCA2a and NCX1 reg-
ulation may further exacerbate the excitation–contraction coupling
defects in HF. The cellular consequences of persistent SR Ca2+ leak
probably include reduced SR Ca2+ loading, which suppresses the
next systolic SR Ca2+ release and contractile event. Additional studies
are required to determine how different post-translational modiﬁca-
tions conspire to generate SR Ca2+ leak in failing hearts, and how
one can intervene therapeutically to restore SR Ca2+ handling and
cardiac function. A better understanding of the molecular mecha-
nisms underlying defects in RyR2 may spur the development of
novel therapeutic approaches to speciﬁcally inhibit SR Ca2+ leak
pathways in HF.
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